Autoimmune Disease News and Research

RSS

Autoimmune Disease is a condition in which the body recognizes its own tissues as foreign and directs an immune response against them.

Seattle enters second ADC research collaboration agreement with Genmab

Genmab A/S and Seattle Genetics, Inc. announced today that the companies have entered into a second antibody-drug conjugate research collaboration agreement.

19 Apr 2011

Abbott submits ARCHITECT 25-OH Vitamin D assay application to FDA for clearance

According to a recent report from the U.S. Centers for Disease Control and Prevention, a third of Americans have vitamin D levels that are either inadequate or deficient. While many people know that vitamin D is necessary to help the body absorb calcium, which helps create strong bones and muscles, many don't know that insufficient levels of this important vitamin may lead to other health problems.

16 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.

15 Apr 2011

Researchers classify chronic ulcerative stomatitis as a new autoimmune disease

In the first study investigating the origins of a little-known condition called chronic ulcerative stomatitis, researchers at Tufts University School of Dental Medicine provide evidence that an autoimmune response contributes to the painful oral sores that characterize the disease. The study findings support the classification of CUS as a new autoimmune disease.

15 Apr 2011

SQI enters clinical validation agreement with University North Carolina Kidney Center for Vasculitis Assay

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced it entered into a clinical validation agreement with University North Carolina Kidney Center, Chapel Hill, to evaluate SQI's new multiplexed, automated approach for biomarker detection in vasculitis.

15 Apr 2011

Early uMSC transplantation may treat lupus nephritis

Human umbilical cord blood-derived mensenchymal stem cells have been found to offer benefits for treating lupus nephritis when transplanted into mouse models of systemic lupus erythematosus.

12 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Seattle Genetics, Inc. today announced that data from a case series of Hodgkin lymphoma patients receiving brentuximab vedotin following allogeneic stem cell transplant were presented in an oral session at the European Group for Blood and Marrow Transplantation Annual Meeting in Paris, France.

7 Apr 2011

ALR announces medical research grant awards to cure lupus

The Alliance for Lupus Research – the world's largest private funder of lupus research – today announced its most recent medical research grant awards, totaling $3.6 million, which support the ALR mission of finding better treatments and ultimately preventing and curing systemic lupus erythematosus, a debilitating autoimmune disease.

7 Apr 2011

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced that it has successfully completed two Phase 1a clinical studies for AVL-292, its orally-available, selective inhibitor of Bruton's tyrosine kinase (Btk).

6 Apr 2011

Avila's PI3Kα inhibitor preclinical study data presented at AACR meeting

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today presented results of preclinical studies on its novel Phosphoinositide 3-kinase alpha inhibitor at the American Association for Cancer Research 102nd Annual Meeting in Orlando, Florida.

6 Apr 2011

NYC scientists receive $420,000 S.L.E. Lupus Foundation grant for new research

New York City's S.L.E. Lupus Foundation is pleased to name the latest recipients of its Career Development and Basic Science Fellowships: Josephine Isgro, MD of Hospital for Special Surgery, Dipyaman Ganguly, PhD of Columbia University Medical Center, and Yi Yan, PhD of the Feinstein Institute at North Shore-Long Island Jewish Hospital.

6 Apr 2011

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Idera Pharmaceuticals, Inc. today announced the presentation of data from its multiple-dose Phase 1 clinical trial of IMO-3100 in healthy subjects.

5 Apr 2011

NAA joins with organizations worldwide to raise awareness about autism

The National Autism Association joins with organizations worldwide in recognizing April as Autism Awareness month. With one in 110 children now diagnosed with autism, and autism mortality rates doubling that of the general population, NAA is once again calling upon legislators and government health agencies to declare autism a national health emergency.

4 Apr 2011

NeoStem revenues increase 13% for the year ended December 31, 2010

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, is today providing unaudited results for 2010 and an update of recent activities.

2 Apr 2011

Lance Sandwich Crackers to support JDRF's Walk to Cure Diabetes

Lance Sandwich Crackers is partnering with the Juvenile Diabetes Research Foundation to support the organization's efforts to find better treatments and a cure for type 1 diabetes.

1 Apr 2011

Broad opportunities for covalent drugs

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced the publication of a scientific review article in Nature Reviews Drug Discovery titled "The Resurgence of Covalent Drugs".

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Positive results from Intercept OCA Phase II trial in patients with PBC

Intercept Pharmaceuticals, Inc., today announced positive results from a 59 patient, placebo controlled, double-blind Phase II clinical trial of obeticholic acid given as monotherapy to patients with primary biliary cirrhosis.

1 Apr 2011

Essential protein linked to TNF induced inflammation

SCIENTISTS have discovered an essential protein that controls inflammation induced by 'tumour necrosis factor' (TNF) - an important part of the body's defences against infection and a driver of cancer-associated inflammation, according to research published in Nature today (Wednesday).

31 Mar 2011